KR102874958B1 - 흡입용 gm-csf의 액상 제제 - Google Patents

흡입용 gm-csf의 액상 제제

Info

Publication number
KR102874958B1
KR102874958B1 KR1020227035847A KR20227035847A KR102874958B1 KR 102874958 B1 KR102874958 B1 KR 102874958B1 KR 1020227035847 A KR1020227035847 A KR 1020227035847A KR 20227035847 A KR20227035847 A KR 20227035847A KR 102874958 B1 KR102874958 B1 KR 102874958B1
Authority
KR
South Korea
Prior art keywords
csf
liquid formulation
rhgm
concentration
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227035847A
Other languages
English (en)
Korean (ko)
Other versions
KR20220154214A (ko
Inventor
라르스 스크리버
앨런 왓츠
Original Assignee
드럭리큐어 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 드럭리큐어 에이피에스 filed Critical 드럭리큐어 에이피에스
Publication of KR20220154214A publication Critical patent/KR20220154214A/ko
Application granted granted Critical
Publication of KR102874958B1 publication Critical patent/KR102874958B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227035847A 2020-03-17 2021-03-17 흡입용 gm-csf의 액상 제제 Active KR102874958B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062990810P 2020-03-17 2020-03-17
US62/990,810 2020-03-17
EP20164648 2020-03-20
EP20164648.6 2020-03-20
PCT/EP2021/056851 WO2021185921A1 (en) 2020-03-17 2021-03-17 Liquid formulation of gm-csf for inhalation

Publications (2)

Publication Number Publication Date
KR20220154214A KR20220154214A (ko) 2022-11-21
KR102874958B1 true KR102874958B1 (ko) 2025-10-21

Family

ID=74871418

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227035847A Active KR102874958B1 (ko) 2020-03-17 2021-03-17 흡입용 gm-csf의 액상 제제

Country Status (12)

Country Link
US (1) US20230201307A1 (enExample)
EP (1) EP4121000A1 (enExample)
JP (2) JP7631358B2 (enExample)
KR (1) KR102874958B1 (enExample)
CN (1) CN115297844A (enExample)
AU (1) AU2021237761B2 (enExample)
BR (1) BR112022018501A2 (enExample)
CA (1) CA3168421A1 (enExample)
IL (1) IL295406A (enExample)
MX (1) MX2022011498A (enExample)
WO (1) WO2021185921A1 (enExample)
ZA (1) ZA202209002B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120324338A (zh) * 2025-06-10 2025-07-18 厦门特宝生物工程股份有限公司 一种重组人粒细胞巨噬细胞刺激因子注射用液体制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020141970A1 (en) 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
WO2007009208A1 (en) * 2005-06-02 2007-01-25 Cangene Corporation Poly(ethylene glocol) modified human gm-csf with increased biological activity
CN100394981C (zh) * 2005-09-16 2008-06-18 深圳市孚沃德生物技术有限公司 一种人粒细胞巨噬细胞集落刺激因子喷雾剂及其制备方法
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
RU2446173C1 (ru) * 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
WO2020002650A1 (en) * 2018-06-29 2020-01-02 Targovax Asa A formulation

Also Published As

Publication number Publication date
JP2025090573A (ja) 2025-06-17
WO2021185921A1 (en) 2021-09-23
JP7631358B2 (ja) 2025-02-18
BR112022018501A2 (pt) 2022-10-25
US20230201307A1 (en) 2023-06-29
CA3168421A1 (en) 2021-09-23
NZ791835A (en) 2025-10-31
AU2021237761B2 (en) 2026-02-05
CN115297844A (zh) 2022-11-04
KR20220154214A (ko) 2022-11-21
JP2023517480A (ja) 2023-04-26
IL295406A (en) 2022-10-01
MX2022011498A (es) 2022-10-07
EP4121000A1 (en) 2023-01-25
ZA202209002B (en) 2025-11-26
AU2021237761A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US12186361B2 (en) Method and formulation for inhalation
JP4338214B2 (ja) エリトロポエチンの肺投与
EP0505123B1 (en) Pulmonary administration of granulocyte colony stimulating factor
CN100333790C (zh) 含白细胞介素－2的药物组合物在制药中的应用
JP2008163033A (ja) エアゾール化医薬の肺への送達
JPH05963A (ja) ポリペプチド類組成物
JP6397984B2 (ja) 乾燥粉末ペプチド医薬
JP2025090573A (ja) 吸入のためのｇｍ－ｃｓｆの液体製剤
US11365248B2 (en) Formulation of tocilizumab and method for treating COVID-19 by inhalation
US20120034202A1 (en) Ameliorating agent for chronic obstructive pulmonary disease
EA049666B1 (ru) Жидкий состав gm-csf для ингаляции
RU2737799C1 (ru) Ингаляционный гексапептид для лечения респираторных заболеваний, связанных с интерлейкином-6
US20250213469A1 (en) Dosage forms of active substances used against viral diseases in dry powder inhaler device for symptoms caused by covid-19 and other viral lung diseases
WO2022005321A1 (en) Inhaled tocilizumab for treating interleukin-6 related respiratory diseases
US20220323546A1 (en) Recombinant interferon

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

A302 Request for accelerated examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

P14 Amendment of ip right document requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P14-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16 Ip right document amended

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16 A copy of ip right certificate issued

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

P14 Amendment of ip right document requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P14-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16 Ip right document amended

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16 A copy of ip right certificate issued

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000